Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy

Completed · Phase 4

Conditions studied: Venous Thromboembolism, Ovarian Cancer

In brief

This is a pilot study to determine the safety and efficacy of low dose aspirin for the prevention of venous thromboembolism among women with advanced ovarian cancer receiving neoadjuvant chemotherapy.

Key facts

Study ID

NCT04352439

Run by

Duke University

People needed

19

Starts

2020-08-08

Expected to finish

2022-03-02

Last updated by the study team

2022-09-26

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Khorana score = 1
• Over age 18
• English-speaking female patients
• Able to consent
• Receiving neoadjuvant chemotherapy Cancer of primary ovarian, fallopian tube, mullerian, or peritoneal origin

You may not qualify if…

• Allergy or intolerance to study medication
• Indication for a non-aspirin form of antiplatelet (i.e. cardiac stent)
• Already on alternative form of anticoagulation
• Active bleeding
• High risk for active bleeding (i.e. recent intracranial bleed or gastrointestinal bleed, known brain metastases)
• Thrombocytopenia (platelets <50,000)
• Unable to complete medication adherence diary
• Unable to take oral medications

Where it is running

• Sarasota Memorial HealthCare System — Sarasota, Florida, United States
• Duke University Hospital — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.